专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2004057341A3 CVD ASSAY 审中-公开
标题翻译： CVD测定
公开(公告)号：WO2004057341A3
公开(公告)日：2004-10-21
申请号：PCT/GB0305607
申请日：2003-12-22
申请人： AXIS SHIELD ASA , SUNDREHAGEN ERLING
发明人： SUNDREHAGEN ERLING
IPC分类号： G01N33/543 , G01N33/68 , G01N33/82
CPC分类号： G01N33/54346 , G01N33/6893 , G01N2333/4727 , G01N2800/32
摘要： An assay method for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject.
摘要翻译：一种用于在人或非人动物受试者中检测CVD或CVD倾向的测定方法，所述方法包括评估取自所述受试者的含钙卫蛋白的样品中的钙卫蛋白的浓度。

22. 发明申请

WO2003069341A2 METHOD OF DIAGNOSIS OF INFLAMMATORY DISEASES USING CALGRANULIN C 审中-公开
标题翻译：使用钙调蛋白C诊断炎症性疾病的方法C
公开(公告)号：WO2003069341A2
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001575
申请日：2003-02-17
申请人： SWITCH BIOTECH AG , SORG, Clemens , ROTH, Johannes
发明人： SORG, Clemens , ROTH, Johannes
IPC分类号： G01N33/564
CPC分类号： G01N33/53 , C12Q1/6883 , C12Q2600/112 , C12Q2600/158 , G01N33/564 , G01N33/6893 , G01N2333/4727 , G01N2333/52 , G01N2800/065
摘要： The present invention is directed to a method for diagnosing inflammatory diseases based on the marker CALGRANULIN C, particularly for diagnosing specific stages of inflammatory diseases and/or for determining the risk of relapse and/or for discriminating between diseases with similar symptoms, said method comprising the steps of (a) obtaining a biological sample of mammalian body fluid or tissue to be diagnosed; (b) determining the amount and/or concentration of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide present in said biological sample; and (c) comparing the amount and/or concentration of CALGRANULIN C polypeptide determine in said biological sample with the amount and/or concentration of CALGRANULIN C polypeptide as determined in a control sample and/or comparing the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptide determined in said biological sample with the amount and/or concentration of nucleic acids encoding CALGRANULIN C polypeptides measured in a control sample, wherein the difference in the amount of CALGRANULIN C polypeptide and/or nucleic acids encoding the polypeptide is indicative for the stages of the disease to be diagnosed.
摘要翻译：本发明涉及一种用于诊断基于标记物CALGRANULIN C的炎性疾病的方法，特别是用于诊断炎性疾病的特定阶段和/或用于确定复发的风险和/或用于区分具有相似症状的疾病的所述方法，所述方法包括获得待诊断的哺乳动物体液或组织的生物样品的步骤b确定存在于所述生物样品中的CALGRANULIN C多肽和/或编码多肽的核酸的量和/或浓度，c将所述量和/或 CALGRANULIN C多肽的浓度在对照样品中测定的CALGRANULIN C多肽的量和/或浓度确定在所述生物样品中，和/或比较在所述生物样品中测定的编码CALGRANULIN C多肽的核酸的量和/或浓度与编码CALGRANULIN C p。的核酸的量和/或浓度在对照样品中测量的双糖，其中CALGRANULIN C多肽和/或编码多肽的核酸的量的差异指示待诊断的疾病的阶段。

23. 发明申请

WO01096878A3 MARKER FOR NEURODEGERATIVE DISEASES AND ITS USE IN DRUG SCREENING 审中-公开
标题翻译：用于治疗神经病毒的药物及其在药物筛选中的应用
公开(公告)号：WO01096878A3
公开(公告)日：2002-06-13
申请号：PCT/BE2001/000100
申请日：2001-06-14
IPC分类号： A61P25/28 , G01N33/68
CPC分类号： G01N33/6896 , G01N2333/4727 , G01N2500/00 , G01N2800/28
摘要： The present invention is related to a diagnostic kit for the detection and/or quantification of a neurodegenerative disease or pathology, comprising an antigenic structure consisting of the calcium-binding protein S100A6 (calcyclin) or comprising an active portion (epitope) thereof, a molecule directed against said antigenic structure (or an active portion thereof) and/or a nucleotide sequence able to hybridise with the nucleotide sequence encoding said protein.
摘要翻译：本发明涉及用于检测和/或定量神经退行性疾病或病理学的诊断试剂盒，其包含由钙结合蛋白S100A6（calcyclin）或包含其活性部分（表位）组成的抗原结构，分子针对所述抗原结构（或其活性部分）和/或能够与编码所述蛋白质的核苷酸序列杂交的核苷酸序列。

24. 发明申请

WO2017123795A1 COMPOUNDS INHIBITING NEF-CALNEXIN INTERACTION 审中-公开
标题翻译：化合物抑制NEF-卡那霉素相互作用
公开(公告)号：WO2017123795A1
公开(公告)日：2017-07-20
申请号：PCT/US2017/013236
申请日：2017-01-12
申请人： THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION , ADZHUBEI, Alexei
发明人： ADZHUBEI, Alexei , BUKRINSKY, Michael , HUNEGNAW, Ruth
IPC分类号： A61K31/122 , A61K31/404 , A61K31/18
CPC分类号： A61K31/404 , A61K31/167 , A61K31/18 , G01N33/502 , G01N2333/163 , G01N2333/4727 , G01N2500/02
摘要： The invention relates to compounds and methods for restoring or preserving cholesterol efflux in a cell infected with Human Immunodeficiency Virus (HIV) by preventing or decreasing an interaction between Negative Regulatory Factor (Nef) protein and Calnexin protein, and methods for screening for such compounds.
摘要翻译：本发明涉及通过预防或减少负调节因子（Nef）蛋白和Calnexin蛋白之间的相互作用来恢复或保持感染人免疫缺陷病毒（HIV）的细胞中的胆固醇流出的化合物和方法，和筛选这些化合物的方法。

25. 发明申请

WO2015158652A8 S100P AND HYLURONIC ACID AS BIOMARKERS FOR METASTATIC BREAST CANCER 审中-公开
标题翻译： S100P和HYLURONIC ACID作为生物标志物用于分子乳腺癌
公开(公告)号：WO2015158652A8
公开(公告)日：2016-10-27
申请号：PCT/EP2015057946
申请日：2015-04-13
申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： BURWINKEL BARBARA , YANG RONGXI , PENG CIKE , SCHNEEWEISS ANDREAS
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2333/4727 , G01N2333/705 , G01N2400/40 , G01N2800/52
摘要： The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of breast cancer in a patient. The method is based on the use of hyaluronic acid and S100P as combined biomarkers in the plasma of breast cancer patients. The new biomarkers of the invention allow diagnosing and even stratifying of breast cancer, in particular metastatic breast cancer. The method provides an interesting alternative to present procedures such as the analysis of the circulating tumor cells (CTC) status. The biomarkers of the invention furthermore allow to monitor therapy success of breast cancer patients and to estimate a patient's prognosis.
摘要翻译：本发明涉及用于诊断，预后，分层和/或监测患者乳腺癌的治疗方法。该方法基于在乳腺癌患者血浆中使用透明质酸和S100P作为组合生物标志物。本发明的新生物标志物允许诊断甚至分层乳腺癌，特别是转移性乳腺癌。该方法提供了一个有趣的替代方案，例如循环肿瘤细胞（CTC）状态的分析。本发明的生物标志物还允许监测乳腺癌患者的治疗成功并估计患者的预后。

26. 发明申请

WO2015158652A3 S1 OOP AND HYLURONIC ACID AS BIOMARKERS FOR METASTATIC BREAST CANCER 审中-公开
标题翻译： S1 OOP和HYLURONIC ACID作为生物标志物用于分子乳腺癌
公开(公告)号：WO2015158652A3
公开(公告)日：2015-12-30
申请号：PCT/EP2015057946
申请日：2015-04-13
申请人： DEUTSCHES KREBSFORSCH
发明人： BURWINKEL BARBARA , YANG RONGXI , PENG CIKE , SCHNEEWEISS ANDREAS
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2333/4727 , G01N2333/705 , G01N2400/40 , G01N2800/52
摘要： The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of breast cancer in a patient. The method is based on the use of hyaluronic acid and S100P as combined biomarkers in the plasma of breast cancer patients. The new biomarkers of the invention allow diagnosing and even stratifying of breast cancer, in particular metastatic breast cancer. The method provides an interesting alternative to present procedures such as the analysis of the circulating tumor cells (CTC) status. The biomarkers of the invention furthermore allow to monitor therapy success of breast cancer patients and to estimate a patient's prognosis.
摘要翻译：本发明涉及用于患者的乳腺癌的治疗的诊断，预后，分层和/或监测的新方法。该方法基于在乳腺癌患者血浆中使用透明质酸和S100P作为组合生物标志物。本发明的新生物标志物允许诊断甚至分层乳腺癌，特别是转移性乳腺癌。该方法提供了一个有趣的替代方案，例如循环肿瘤细胞（CTC）状态的分析。本发明的生物标志物还允许监测乳腺癌患者的治疗成功并估计患者的预后。

27. 发明申请

WO2015078711A2 METHODS, PEPTIDES AND ANTIBODIES FOR PREVENTING, TREATING AND DIAGNOSING AN INFLAMMATORY CONDITION 审中-公开
标题翻译：方法，用于预防，治疗和诊断炎症症状的肽和抗体
公开(公告)号：WO2015078711A2
公开(公告)日：2015-06-04
申请号：PCT/EP2014074719
申请日：2014-11-17
申请人： UNIV MUENSTER WILHELMS
发明人： ROTH JOHANNES , VOGL THOMAS
IPC分类号： C07K14/435
CPC分类号： C07K7/08 , A61K38/00 , C07K14/001 , C07K14/705 , C07K16/18 , C07K16/2896 , C07K16/44 , G01N33/68 , G01N2333/47 , G01N2333/4727 , G01N2333/70596 , G01N2500/02 , G01N2500/20
摘要： Provided is an isolated peptide or a peptidomimetic comprising a sequence corresponding to amino acid positions 431-616 or 411-616 of the human protein TLR4 or corresponding to amino acid positions 84-131 of the human protein MD-2. Provided is also an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 411 to 616 of variant 1 the human protein TLR4. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 86 to 131 of the human protein MD2. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between one of the above peptides or whole molecules and an S100A8 or S100A9 or S100A8/S100A9 protein or a functional fragment thereof.
摘要翻译：提供了分离的肽或肽模拟物，其包含对应于人蛋白质TLR4的氨基酸位置431-616或411-616或对应于人蛋白质MD-2的氨基酸位置84-131的序列。还提供了对于表位的特异性的抗体，所述表位是对应于变体1的人类蛋白质TLR4的氨基酸位置411至616的区域。还提供了对于表位的特异性的抗体，其是对应于人蛋白质MD2的氨基酸位置86至131的区域。此外，还提供了这种抗体在治疗或诊断炎症性疾病中的用途。还提供了鉴定能够抑制上述肽或整个分子之一的复合物形成的化合物和S100A8或S100A9或S100A8 / S100A9蛋白或其功能片段的体外方法。

28. 发明申请

WO2013191146A1 KIT FOR DIAGNOSING MALIGNANT MELANOMA 审中-公开
标题翻译：用于诊断恶性肿瘤的试剂盒
公开(公告)号：WO2013191146A1
公开(公告)日：2013-12-27
申请号：PCT/JP2013066631
申请日：2013-06-17
申请人： NAT CANCER CT , LSIP LLC
发明人： NAKATSURA TETSUYA , SAITO KEIGO
IPC分类号： G01N33/574 , C07K16/18 , C07K16/28 , C12N5/10 , C12P21/08 , G01N33/543 , G01N33/577
CPC分类号： G01N33/5743 , C07K16/18 , C07K16/22 , C07K16/303 , C07K16/3053 , C07K2319/00 , C12N5/16 , C12N2510/02 , G01N33/577 , G01N2333/4722 , G01N2333/4727
摘要： Provided is a kit for diagnosing melanoma at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
摘要翻译：提供了用于以高再现性诊断黑素瘤的试剂盒，所述试剂盒通过制备针对GPC3的单克隆抗体和针对SPARC的单克隆抗体产生，其针对市售和常用抗体的质量稳定性优异，并且使用这些抗体。

29. 发明申请

WO2013083781A2 BIOMARKERS AND TEST PANELS USEFUL IN SYSTEMIC INFLAMMATORY CONDITIONS 审中-公开
标题翻译：生物标记和测试面板有用的系统性的炎症条件
公开(公告)号：WO2013083781A2
公开(公告)日：2013-06-13
申请号：PCT/EP2012/074806
申请日：2012-12-07
申请人： PRONOTA N.V.
发明人： VANPOUCKE, Griet , VERLEYSEN, Katleen , VAN HERREWEGE, Yven
IPC分类号： C07K14/00
CPC分类号： G01N33/6893 , G01N2333/47 , G01N2333/4727 , G01N2333/705 , G01N2333/70525 , G01N2333/70535 , G01N2333/70542 , G01N2333/7155 , G01N2333/75 , G01N2333/91097 , G01N2333/916 , G01N2333/96425 , G01N2333/96433 , G01N2800/26 , G01N2800/52 , G01N2800/7095
摘要： The application discloses new biomarkers or test panels useful in systemic inflammatory conditions such as sepsis; methods for the diagnosis, prediction, prognosis and/or monitoring systemic inflammatory conditions such as sepsis based on measuring said biomarkers or test panels; and related kits and devices.
摘要翻译：该应用公开了可用于全身炎症病症如败血症的新生物标志物或测试板; 用于诊断，预测，预后和/或监测基于测量所述生物标志物或测试板的全身性炎症病症如败血症的方法; 和相关的工具包和设备。

30. 发明申请

WO2013016425A9 FECAL NEOPTERIN CONCENTRATION MEASUREMENT AS AN INDICATOR OF DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： FECAL NEOPTERIN浓度测量作为炎症性皮肤疾病中疾病活动的指标
公开(公告)号：WO2013016425A9
公开(公告)日：2013-05-16
申请号：PCT/US2012048143
申请日：2012-07-25
申请人： UNIV NORTHWESTERN , BUCHMAN ALAN L
发明人： BUCHMAN ALAN L
IPC分类号： G01N33/53 , G01N33/72
CPC分类号： G01N33/5308 , G01N15/05 , G01N33/492 , G01N33/6893 , G01N2015/055 , G01N2333/46 , G01N2333/4727 , G01N2333/4737 , G01N2333/765 , G01N2333/79 , G01N2333/805 , G01N2800/065 , G01N2800/50 , G01N2800/56

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式